Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CDC25B | P30305 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | SLC15A1 | P46059 | 2/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4268842 | 0.86 | ALDH1A1 (0.45) | ALDH1A1MAPK1L3MBTL1TDP1LMNA | |
| SCHEMBL14102854 | 0.81 | ALDH1A1 (0.51) | ALDH1A1MAPK1L3MBTL1TDP1LMNA | |
| SCHEMBL7624952 | 0.81 | ALDH1A1 (0.42) | ALDH1A1MAPK1L3MBTL1LMNACDC25B | |
| SCHEMBL14102849 | 0.80 | ALDH1A1 (0.40) | ALDH1A1MAPK1L3MBTL1LMNACDC25B | |
| SCHEMBL14145006 | 0.80 | ALDH1A1 (0.46) | ALDH1A1MAPK1L3MBTL1TDP1LMNA | |
| SCHEMBL7048037 | 0.80 | ALDH1A1 (0.46) | ALDH1A1MAPK1L3MBTL1TDP1LMNA | |
| SCHEMBL9506271 | 0.79 | HSD17B10 (0.49) | ALDH1A1 | |
| SCHEMBL14102855 | 0.79 | ALDH1A1 (0.49) | ALDH1A1MAPK1L3MBTL1TDP1LMNA | |
| SCHEMBL7505198 | 0.79 | HSD17B10 (0.49) | ALDH1A1 | |
| SCHEMBL17943283 | 0.79 | ALDH1A1 (0.41) | ALDH1A1MAPK1L3MBTL1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583887-B2 | PSMA imaging agents | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-12559521-B2 | PSMA imaging agents | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| EP-4097119-B1 | BILE ACID-GCPII INHIBITOR CONJUGATES TO TREAT INFLAMMATORY DISEASES | UNIV JOHNS HOPKINS (US) | 2025-05-07 | — | — | EP | disclosed |
| US-20240425547-A1 | PSMA Imaging Agents | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2024-12-26 | — | — | US | disclosed |
| US-20240409580-A1 | PSMA Imaging Agents | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2024-12-12 | — | — | US | disclosed |
| US-12139554-B2 | PSMA imaging agents | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2024-11-12 | — | — | US | disclosed |
| US-12122851-B2 | PSMA imaging agents | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2024-10-22 | — | — | US | disclosed |
| US-20230128984-A1 | BILE ACID-GCPII INHIBITOR CONJUGATES TO TREAT INFLAMMATORY DISEASES, INCLUDING INFLAMMATORY BOWEL DISEASE (IBD) | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I. (CZ) | 2023-04-27 | — | — | US | disclosed |
| EP-4097119-A1 | BILE ACID-GCPII INHIBITOR CONJUGATES TO TREAT INFLAMMATORY DISEASES | The Johns Hopkins University (US) | 2022-12-07 | — | — | EP | disclosed |
| WO-2021155167-A1 | BILE ACID-GCPII INHIBITOR CONJUGATES TO TREAT INFLAMMATORY DISEASES | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-08-05 | — | — | WO | disclosed |
| EP-0936914-A1 | HYDROXY-PHOSPHINYL DERIVATIVES USEFUL AS NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1999-08-25 | — | — | EP | disclosed |
| EP-0936914-A4 | — | — | 1999-08-25 | — | — | EP | disclosed |
| WO-1999033849-A1 | PRODRUGS OF NAALADASE INHIBITORS | GUILDFORD PHARMACEUTICALS INC. (US) | 1999-07-08 | — | — | WO | disclosed |
| WO-1998053812-A1 | INHIBITORS OF NAALADASE ENZYME ACTIVITY | GUILFORD PHARMACEUTICALS INC. (US) | 1998-12-03 | — | — | WO | disclosed |
| WO-1998047906-A1 | PHOSPHONIC ACID DERIVATIVES | GUILFORD PHARMACEUTICALS INC. (US) | 1998-10-29 | — | — | WO | disclosed |
| WO-1998013044-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-04-02 | — | — | WO | disclosed |
| WO-1998013046-A1 | NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-04-02 | — | — | WO | disclosed |
| WO-1997048399-A1 | CERTAIN PHOSPHINYL DERIVATIVES USEFUL AS NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1997-12-24 | — | — | WO | disclosed |
| WO-1997048400-A1 | HYDROXY-PHOSPHINYL DERIVATIVES USEFUL AS NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1997-12-24 | — | — | WO | disclosed |
| WO-1997048409-A1 | METHODS OF CANCER TREATMENT USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1997-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240425547-A1 | PSMA Imaging Agents | FOLH1, KLK3, PSMA2 | ALDH1A1 3049/4885MAPK1 4335/4885L3MBTL1 4197/4885 |
| US-20240409580-A1 | PSMA Imaging Agents | FOLH1, KLK3, PSMA2 | ALDH1A1 3049/4885MAPK1 4335/4885L3MBTL1 4197/4885 |
| US-20230128984-A1 | BILE ACID-GCPII INHIBITOR CONJUGATES TO TREAT INFLAMMATORY DISEASES, INCLUDING INFLAMMATORY BOWEL DISEASE (IBD) | SLC10A2, GPBAR1, NR1H4 | ALDH1A1 2119/4885MAPK1 554/4885L3MBTL1 4481/4885 |
| US-12559521-B2 | PSMA imaging agents | KLK3, PSMA1, PSMA6 | ALDH1A1 2393/4885MAPK1 3950/4885L3MBTL1 2844/4885 |
| US-12139554-B2 | PSMA imaging agents | FOLH1, KLK3, PSMA2 | ALDH1A1 3049/4885MAPK1 4335/4885L3MBTL1 4197/4885 |
| US-12583887-B2 | PSMA imaging agents | KLK3, PSMA3, PSMA1 | ALDH1A1 2109/4885MAPK1 4404/4885L3MBTL1 3753/4885 |
| US-12122851-B2 | PSMA imaging agents | FOLH1, KLK3, PSMA2 | ALDH1A1 3049/4885MAPK1 4335/4885L3MBTL1 4197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.